10 terminated. 10 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Terminated 10 |
| Phase 1 | 5 | Terminated 5 |
Follow IFL protocol: new trials by email Literature Review of IFL protocol trials Research Report on IFL protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies SI-B001, Irinotecan, FOLFIRI Protocol - Colorectal Cancer | Phase 2 | Terminated | Sichuan Baili Pharmaceutical Co., Ltd. | 7 | 2021-11-30 | 2024-07-18 |
| Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC NIS793, Bevacizumab, Modified FOLFOX6 - Metastatic Colorectal Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 204 | 2021-11-15 | 2025-03-26 |
| A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy OFF, FOLFIRI Protocol - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | AIO-Studien-gGmbH | 67 | 2018-01-02 | 2022-01-11 |
| Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels FOLFOXIRI, FOLFOX, FOLFIRI - Metastatic Colorectal Cancer | Phase 2 | Terminated | Centre Hospitalier Universitaire de Besancon | 54 | 2017-08-04 | 2025-02-05 |
| Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients Sym004, FOLFIRI - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Symphogen A/S | 10 | 2016-03-15 | 2019-03-26 |
| A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer PF-05212384, FOLFIRI regimen, Bevacizumab - Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Terminated | Pfizer | 18 | 2014-02-01 | 2016-08-18 |
| Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer aflibercept + FOLFIRI - Metastatic Colorectal Cancer | Phase 2 | Terminated | CR-CSSS Champlain-Charles-Le Moyne | 14 | 2014-01-01 | 2016-11-16 |
| Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer FOLFIRI, E7820 - Colon Cancer, Rectal Cancer | Phase 1 / Phase 2 | Terminated | Eisai Inc. | 82 | 2011-09-30 | 2023-06-22 |
| FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer FOLFIRI, E7820, Bevacizumab - Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Eisai Inc. | 5 | 2010-03-04 | 2023-11-07 |
| MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) Pimasertib, Placebo, FOLFIRI - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Terminated | EMD Serono | 16 | 2010-03-01 | 2016-10-19 |
Colorectal Neoplasms (8) · Colonic Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Rectal Neoplasms (1)
Eisai Inc. (2) · AIO-Studien-gGmbH (1) · CR-CSSS Champlain-Charles-Le Moyne (1) · Centre Hospitalier Universitaire de Besancon (1) · EMD Serono (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1) · Symphogen A/S (1)
United States (5) · Spain (4) · Australia (3) · Canada (3) · Belgium (2) · France (2) · Germany (2) · Italy (2) · Russia (2) · Ukraine (2) · Argentina (1) · Brazil (1) · China (1) · Czechia (1) · Hong Kong (1)
Harish Dave (2) · Benoit Samson, MD (1) · Josep Tabernero, MD, PhD (1) · Weijian Guo (1)
2009 (1), 2015 (1)